Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 900

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 900
---
 associated with commercial banking relationships. The short-term investments consist of U.S. Treasury Notes which the Company believes represent minimal credit risk. The following table presents information about the Company’s significant suppliers:

| ​        
 ​        | ​ 
 ​ | ​ 
 ​ | For the Year EndedDecember 31, 
 2023                           |   |     |   | ​ | ​ | 2022 |   |     |   | ​ 
 ​ | ​ 
 ​ | As ofDecember 31,    
 2023                 |   |     |   | ​ | ​ | 2022 |   |     |   | ​ 
 ​ |
|:---------|:--|:--|:-------------------------------|:--|:----|:--|:--|:--|:-----|:--|:----|:--|:--|:--|:---------------------|:--|:----|:--|:--|:--|:-----|:--|:----|:--|:--|
| ​        | ​ | ​ | % of operatingexpenses         |   |     |   |   |   |      |   |     |   | ​ | ​ | % of accountspayable |   |     |   |   |   |      |   |     |   | ​ |
| Vendor A | ​ | ​ | ​                              | ​ | 33% | ​ | ​ | ​ | ​    | ​ | 28% | ​ | ​ | ​ | ​                    | ​ | 40% | ​ | ​ | ​ | ​    | ​ | 42% | ​ | ​ |
| Vendor B | ​ | ​ | ​                              | ​ | 14% | ​ | ​ | ​ | ​    | ​ | 9%  | ​ | ​ | ​ | ​                    | ​ | —   | ​ | ​ | ​ | ​    | ​ | 27% | ​ | ​ |
| Vendor C | ​ | ​ | ​                              | ​ | 8%  | ​ | ​ | ​ | ​    | ​ | 7%  | ​ | ​ | ​ | ​                    | ​ | 10% | ​ | ​ | ​ | ​    | ​ | 8%  | ​ | ​ |
| Vendor D | ​ | ​ | ​                              | ​ | —   | ​ | ​ | ​ | ​    | ​ | —   | ​ | ​ | ​ | ​